| Literature DB >> 31983047 |
Harsimran Kaur1, Shamanth A Shankarnarayana1, Vinaykumar Hallur2, Jayashree Muralidharan3, Manisha Biswal1, Anup K Ghosh1, Pallab Ray1, Arunaloke Chakrabarti1, Shivaprakash M Rudramurthy4.
Abstract
BACKGROUND: A sudden rise of Candida krusei candidemia cases was noticed in our hospital within 1 year with maximum cases from paediatric unit. The present study reports the results of epidemiological investigation of possible outbreak of candidemia by C. krusei in paediatric unit at our tertiary care centre.Entities:
Keywords: Candida krusei; Candidemia; Molecular typing; Outbreak; Paediatrics
Mesh:
Substances:
Year: 2020 PMID: 31983047 PMCID: PMC7222167 DOI: 10.1007/s11046-020-00427-y
Source DB: PubMed Journal: Mycopathologia ISSN: 0301-486X Impact factor: 2.574
Fig. 1Flowchart showing different wards with the number of beds and C. krusei cases in each ward and ICUs
Fig. 2Month-wise distribution of paediatric candidemia cases by C. krusei, C. tropicalis and C. pelliculosa
Fig. 3Ward-wise distribution of paediatric candidemia cases by C. krusei
Evaluation of clinical characteristics of C. krusei candidemia cases in paediatric ward
| ( | ( | ( | |||
|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | |||
| Total | 65 (79.3) | 25 (69.4) | 22 (81.5) | 0.248 | 0.804 |
| Males | 47 (72.4) | 17 (68) | 16 (72.7) | ||
| Females | 18 (27.6) | 8 (32) | 6 (27.3) | ||
| Total | 17 (20.7) | 11 (30.6) | 5 (18.5) | 0.248 | 0.804 |
| Males | 11 (64.7) | 6 (54.5) | 5 (100) | ||
| Females | 6 (35.3) | 5 (45.5) | 0 (0) | ||
| Age [median (IQR)] | 13 days (6–28 days) | 14 days (4–112 days) | 13 days (2–28 days) | 0.865 | 0.296 |
| Days to positivity to blood culture (median, IQR) | 2 (1–4) days | 5 (1–13.75) days | 1 (1–3) days | 0.794 | |
| Congenital malformations | 14 (17.1) | 16 (44.4) | 1 (3.7) | 0.248 | |
| Gastrointestinal | 20 (24.4) | 15 (41.7) | 1 (3.7) | 0.059 | |
| Late onset neonatal sepsis | 28 (34.1) | 11 (30.6) | 8 (29.6) | 0.703 | 0.665 |
| Early onset neonatal sepsis | 10 (2.8) | 1 (2.8) | 5 (18.5) | 0.095 | 0.297 |
| Neurological | 13 (15.9) | 4 (11.1) | 4 (14.8) | 0.499 | 0.584 |
| Jaundice | 4 (4.9) | 2 (5.6) | 0 (0) | 0.596 | 0.314 |
| Cardiac | 3 (3.7) | 2 (5.6) | 1 (3.7) | 0.484 | 0.686 |
| Renal | 1 (1.2) | 0 (0) | 2 (7.4) | 0.695 | 0.151 |
| Infection | 5 (6.1) | 3 (8.3) | 3 (11.1) | 0.463 | 0.312 |
| Gastroenteritis | 5 (6.1) | 1 (2.8) | 1 (3.7) | 0.404 | 0.537 |
| Tetanus | 0 (0) | 1 (2.8) | 1 (3.7) | 0.305 | 0.248 |
| Prematurity | 9 (11) | 3 (8.3) | 3 (11) | 0.754 | 0.613 |
| ALL | 0 (0) | 1 (2.8) | 0 (0) | 0.305 | - |
| ICU admission | 19 (23.2) | 17 (47.2) | 2 (7.4) | 0.072 | |
| Urinary catheter | 5 (6.1) | 2 (5.6) | 0 (0) | 0.637 | 0.234 |
| Central line catheter | 1 (1.2) | 3 (8.3) | 0 (0) | 0.084 | 0.752 |
| Nasogastric/orogastric tube | 9 (11) | 7 (19.4) | 4 (14.8) | 0.171 | 0.407 |
| Endotracheal tube | 6 (7.3) | 3 (8.3) | 0 (0) | 0.556 | 0.173 |
| Mechanical ventilation | 15 (18.3) | 16 (44.4) | 2 (7.4) | 0.147 | |
| Antibiotics | 24 (29.3) | 13 (36.1) | 2 (7.4) | 0.461 | |
| Vancomycin | 15 (18.3) | 8 (22.2) | 1 (3.7) | 0.620 | 0.052 |
| Piperacillin–tazobactam | 3 (3.7) | 1 (2.8) | 1 (3.7) | 0.643 | 0.686 |
| Aminoglycosides | 15 (18.3) | 5 (13.9) | 2 (7.4) | 0.557 | 0.147 |
| Carbapenems | 16 (19.5) | 7 (19.4) | 1 (3.7) | 0.993 | |
| Cephalosporins | 8 (9.8) | 1 (2.8) | 1 (3.7) | 0.176 | 0.294 |
| Metronidazole | 2 (2.4) | 4 (11.1) | 1 (3.7) | 0.069 | 0.578 |
| Erythromycin | 2 (2.4) | 0 (0) | 0 (0) | 0.481 | 0.564 |
| 17 (23) | 15 (42.9) | 4 (14.8) | 0.371 | ||
ALL acute lymphoblastic leukaemia, ICU intensive care unit, IQR interquartile range, italicized words in the first column indicates the group under which different factors/parametes were analysed
*Statistically significant
Fig. 4Year-wise trend in paediatric candidemia cases caused by C. krusei and hand hygiene compliance in paediatric units
In-vitro antifungal susceptibility data (MIC, mg/L) of 82 C. krusei isolates against seven antifungal drugs
| Antifungals | GM | Range | MIC 50 | MIC 90 |
|---|---|---|---|---|
| Amphotericin B | 0.896341 | 0.25–2 | 1 | 1 |
| Voriconazole | 0.413049 | 0.05–8 | 0.25 | 0.25 |
| Itraconazole | 0.305132 | 0.12–0.5 | 0.25 | 0.5 |
| Posaconazole | 0.24122 | 0.06–0.5 | 0.25 | 0.5 |
| Caspofungin | 0.350802 | 0.12–2 | 0.12 | 0.5 |
| Anidulafungin | 0.275976 | 0.03–4 | 0.12 | 0.5 |
| Micafungin | 0.447805 | 0.06–12 | 0.12 | 0.5 |
GM geometric mean, MIC minimum inhibitory concentration
Fig. 5Fingerprint profile generated by FAFLP analysis of C. krusei isolated from blood and environment in the year 2014
Fig. 6Fingerprint profile generated by FAFLP analysis of C. krusei isolated over different years
Literature review of outbreaks due to Candida krusei worldwide
| Sl no | Year | Country | Hospital area | Risk factor | Patients/HCW/environment | Duration | Origin | Typing method | References |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 1996 | USA | Haemato-oncology | Fluconazole prophylaxis | 4/–/– | 1 month | Genotype A/A1 | REA | Noskin et al. |
| 2 | 2006 | Netherlands | Haemato-oncology | Fluconazole prophylaxis | 13/–/– | 2.5 years | Genotype 1/6/8 | CKTNR/CKRS1 assay | Vos et al. |
| 3 | 2007 | Finland | Haemato-oncology | Fluconazole prophylaxis | 6/–/2 (sink trap) | 1 month | Same cluster | CHEF PFGE | Hautala et al. |
| 4 | 2011 | Portugal | Neutropenia unit of haematology | Fluconazole prophylaxis ( | 3/–/2 (surfaces) | 2 months | Related strains | REA | Ricardo et al. |
| 5 | 2012 | Brazil | NICU | Fluconazole prophylaxis ( | 3/–/– | 3 years | NA | NA | Selma Amaral-Lopes et al. |
| Fluconazole therapy ( | |||||||||
| Premature | |||||||||
| 6 | 2014 | India | NICU | Prematurity | 7/–/1 (multi-electrolyte dextrose infusate) | 11 days | Clonal | RAPD | Rongpharpi et al. |
| 7 | 2015 | India (2 outbreaks) | NICU | Prematurity, low birth weight | (a) 2/–/1 (multi-electrolyte dextrose infusate) | (a) 2 days | Related | RAPD | Duggal et al. |
| (b) 4/–/1 (suction apparatus) | (b) 10 days | ||||||||
| 8 | 2018 | South Africa (2 outbreaks) | Neonatal unit | Neonates | (a) 48/–/– | Both 4 months | NA | NA | van Schalkwyk et al. |
| (b) 41/–/– | |||||||||
| 9 | 2018 | India | Paediatric unit | Paediatrics including Neonates | 82/1/1 (hands of healthcare worker and washbasin) | 1 year | Clonal | FAFLP | Present study |
FAFLP fluorescent amplified fragment length polymorphism, HCW health care workers, NA not available, NICU neonatal intensive care unit, PFGE pulse field gel electrophoresis, RAPD random amplified polymorphic DNA, REA restriction endonuclease assay, USA United States of America